RELATED STORY | Weight-loss pill from Wegovy makers cut body weight by up to 13% in early trial Novo Nordisk brought numerous lawsuits against the FDA and companies selling compounded versions of the drugs
What Both Medications Do Inside the Body Although the delivery systems differ, both medications activate the GLP-1 receptor and trigger similar downstream effects: Increased insulin release in response to elevated blood sugar Reduced glucagon secretion Slower gastric emptying Reduced appetite signaling Increased satiety after meals According to the National Institute of Diabetes and Digestive and Kidney Diseases, these mechanisms can support improved blood sugar regulation and meaningful weight reduction when combined with lifestyle interventions
GLP-1 agonists: act on the metabolism upstream by extrahepatic path The emergence of glucagon-like peptide-1 (GLP-1) agonists as a treatment option for diabetes and obesity has prompted their examination in patients with MASH 5
Outside that window, the brand states replacements generally can't be approved - though they note occasional exceptions for situations like hospitalization
The confusion comes from rapid water weight fluctuations in the first 2-3 weeks after stopping
They act on appetite centers, so you feel full sooner and think less about food
